Gastroenterology News & Research | Hospital Healthcare Europe

This website is intended for healthcare professionals only.

Gastroenterology

Adalimumab biosimilar Imraldi launched in European Union

Adalimumab biosimilar Imraldi launched in European Union

Coeliac disease diagnosis rises to 30% – but still missing half a million

Coeliac disease diagnosis rises to 30% – but still missing half a million

EC approves early dose optimisation of Simponi for ulcerative colitis patients

EC approves early dose optimisation of Simponi for ulcerative colitis patients

Peanut allergy drug passes clinical trial

Peanut allergy drug passes clinical trial

Biosimilar infliximab comparable to reference product and adalimumab in real-world study

Biosimilar infliximab comparable to reference product and adalimumab in real-world study

Therapy for the prevention of recurrence of Clostridium difficile infection is launched in the UK

Therapy for the prevention of recurrence of Clostridium difficile infection is launched in the UK

Bowel Cancer UK identifies critical research gaps

Bowel Cancer UK identifies critical research gaps

Adalimumab biosimilar approved in Europe for the treatment of multiple chronic inflammatory diseases

Adalimumab biosimilar approved in Europe for the treatment of multiple chronic inflammatory diseases

One-year results for biosimilar infliximab switching study in Crohn’s disease

One-year results for biosimilar infliximab switching study in Crohn’s disease

Symptom improvement in moderately to severely active Crohn’s disease with ustekinumab

Symptom improvement in moderately to severely active Crohn’s disease with ustekinumab

Guideline for the management of nut allergy helps to define diagnostic pathways, including the role of specific IgE testing

Positive CHMP opinion for adalimumab biosimilar

Positive CHMP opinion for adalimumab biosimilar

Eluxadoline receives final approval from NICE for the treatment of IBS with diarrhoea

Eluxadoline receives final approval from NICE for the treatment of IBS with diarrhoea

Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA

Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA

Treating paediatric short bowel syndrome

Use of extended-pulsed regimen with fidaxomicin more effective than standard vancomycin in CDI

Use of extended-pulsed regimen with fidaxomicin more effective than standard vancomycin in CDI

NICE recommends Stelara for moderate to severe Crohn’s disease

NICE recommends Stelara for moderate to severe Crohn’s disease

×